Brief: Supernus Pharmaceuticals Q4 Product Sales USD 166.4 Million
25/02/2025 21:02
Feb 25 (Reuters) - Supernus Pharmaceuticals Q4 operating earnings USD 21.405 million. Q4 adjusted revenue USD 146.2 million vs. IBES estimate USD 155.3 million outlook FY revenue USD 600-630 million outlook FY adjusted operating earnings USD 105-130 million
Recent news on Supernus Pharmaceuticals
See all newsHuron Consulting poised to hit fresh record ahead of S&P SmallCap addition
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing